Pharmacologic measures for primary prevention: Lipid lowering drugs, aspirin, drug therapy of obesity and hypertension;Pharmakologische maßnahmen in der primärprävention: Lipidsenker, aspirin, antiadiposita und antihypertensiva

Wiener Medizinische Wochenschrift

Volumn 151, Issue 1-2, 2001, Pages 13-17

  Auer, J ^a   Berent, R ^a   Weber, T ^a   Porodko, M ^a   Mayr, H ^a   Maurer, E ^a   Eber, B ^a  

^a Interne Abteilung mit Kardiologie   (Austria)

Author keywords

Cardiovascular disease; Drug therapy; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLECYSTOKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRINE; GLUCAGON; GLUCAGON LIKE PEPTIDE; LEPTIN; MAZINDOL; NEUROPEPTIDE Y; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; ANTITHROMBOCYTIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; OBESITY; PRIMARY PREVENTION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; COST BENEFIT ANALYSIS; METHODOLOGY; RISK; RISK FACTOR;

ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK; RISK FACTORS;

EID: 0035137257     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Pharmacologic treatment of obesity
2. Contemporary diagnosis and management of obesity
3. The Women's Health Study: Summary of the study design
4. Antithrombotic agents in coronary artery disease
5. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
6. Weight gain as a risk factor for clinical diabetes mellitus in women
7. Valvular heart disease associated with fenfluraminephentermine
8. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: Interim Results
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
10. Weight loss reduces the risk for symptomatic knee osteoarthritis in women
11. Is pulse pressure useful in predicting risk for coronary heart disease?
12. The pathogenesis of coronary artery disease and the acute coronary syndromes
13. Long term weight loss - The effect of pharmacological agents
14. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
15. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease
16. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association
17. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
18. Blood pressure as a cardiovascular risk factor
19. Physiological and medical concomitants of obesity: The Framingham study
20. Lifetime risk of developing coronary heart disease
21. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal intervention study
22. Impact of major cardiovascular disease risk factors, particularly in combination, on 22 year mortality in women and men
23. Blood pressure, stroke, and coronary heart disease. Part I; Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
24. Body weight and mortality among women
25. A randomised trial of the effects of prophylactic daily aspirin among male British doctors
26. Prevention of coronary heart disease with pravastatin in men with hypercholesterinemia
27. Final report on the aspirin component of the ongoing Physicians' Health Study
28. Weight loss intervention in phase I of the Trials of Hypertension Prevention
29. The Six Report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure
30. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
31. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
32. Diet and exercise in the treatment of obesity. Effects of three interventions on insulin resistance
33. Determinants of isolated systolic hypertension
34. Prospective study of intentional weight-loss and mortality in never-smoking overweight US white women aged 40-64
35. Established risk factors and coronary artery disease: The Framingham Study